Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.35
$160.36
▼
$261.00
$37.20B0.11.21 million shs838,745 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$51.57
+0.4%
$41.15
$23.62
▼
$59.97
$32.18B0.732.57 million shs2.41 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.61
-2.3%
$37.31
$19.96
▼
$42.50
$27.89B1.236.59 million shs8.73 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$99.37
-4.5%
$91.48
$23.01
▼
$110.64
$9.44B3.241.13 million shs824,685 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+2.03%+8.92%+21.16%+51.24%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%-4.21%+38.84%+56.43%+69.76%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%+1.67%+17.89%+9.08%+94.83%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%+0.13%+30.16%-0.57%+342.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$251.65
-0.7%
$233.35
$160.36
▼
$261.00
$37.20B0.11.21 million shs838,745 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$51.57
+0.4%
$41.15
$23.62
▼
$59.97
$32.18B0.732.57 million shs2.41 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$38.61
-2.3%
$37.31
$19.96
▼
$42.50
$27.89B1.236.59 million shs8.73 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$99.37
-4.5%
$91.48
$23.01
▼
$110.64
$9.44B3.241.13 million shs824,685 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
0.00%+2.03%+8.92%+21.16%+51.24%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%-4.21%+38.84%+56.43%+69.76%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%+1.67%+17.89%+9.08%+94.83%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%+0.13%+30.16%-0.57%+342.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$254.411.10% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3.00
Buy$53.503.74% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.79
Moderate Buy$46.8221.26% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
2.94
Moderate Buy$110.5311.23% Upside

Current Analyst Ratings Breakdown

Latest SYRE, BIIB, GMAB, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$46.00 ➝ $48.00
11/13/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Lower Price TargetEqual Weight$57.00 ➝ $56.00
11/10/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Boost Price TargetBuy$47.00 ➝ $48.00
11/9/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
UpgradeHold (C+) ➝ Buy (B-)
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/4/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Boost Price TargetBuy$130.00 ➝ $135.00
11/4/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Lower Price TargetOutperform$123.00 ➝ $120.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Boost Price TargetBuy$251.00 ➝ $270.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Boost Price TargetEqual Weight$42.00 ➝ $57.00
10/30/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Boost Price TargetBuy$58.00 ➝ $80.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$10.30B3.61$22.49 per share11.19$124.45 per share2.02
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$4.30B7.49$1.62 per share31.91$9.10 per share5.67
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$41.08M678.86N/AN/A$7.35 per share5.25
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/A$7.21 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34107.5415.792.873.37%9.38%5.69%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.1744.0832.432.0716.97%13.67%6.42%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.63N/AN/AN/A-838.21%-22.03%-20.55%N/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$2.74N/AN/AN/AN/A-35.97%-27.67%N/A

Latest SYRE, BIIB, GMAB, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.36$0.56+$0.20$0.5510$1.20 billion$1.19 billion
11/3/2026Q3 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.8223-$0.94-$0.1177-$0.94N/AN/A
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.74
2.45
2.43
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
15.56
15.56
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
27.40
27.40

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
8.80%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
721722.32 million660.80 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
13094.97 million80.07 millionOptionable

Recent News About These Companies

Spyre Therapeutics Announces Grants of Inducement Awards

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biogen stock logo

Biogen NASDAQ:BIIB

$251.65 -1.75 (-0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$251.85 +0.20 (+0.08%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$51.57 +0.20 (+0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$51.56 -0.02 (-0.03%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$38.61 -0.92 (-2.33%)
Closing price 04:00 PM Eastern
Extended Trading
$38.69 +0.08 (+0.22%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$99.37 -4.63 (-4.45%)
Closing price 04:00 PM Eastern
Extended Trading
$99.38 +0.00 (+0.01%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.